(Press-News.org) The first of the selected abstracts came from Wolfgang Merkt, who presented an update on a patient who originally received third-generation CD19-CAR-T cells in 2022. This patient had a rapidly progressive form of systemic sclerosis (SSc) with interstitial lung disease with fatal prognosis. The authors report that CAR-T cells and B cell depletion persisted over 24 months, with stable serological remission and major disease improvement. Of note, fibrotic lesions and areas of activated fibroblasts further regressed in the second year of treatment – after prolonged deep B cell depletion and the achievement of serologic remission.
Resecabtagene autoleucel is a fully human, autologous 4-1BB anti-CD19-CAR T cell therapy, designed to deeply and transiently deplete CD19 positive cells following a weight-based, one-time infusion. Results were presented from RESET-SScTM – a Phase 1/2 trial in SSc with either severe skin or organ involvement. Dinesh Khanna described initial findings from 3-month follow-up in three patients, which demonstrate early immunomodulatory free clinical response, and deep B cell depletion in the tissue as evidenced by lymph node biopsy.
RESET-MyositisTM explored the same agent in three patients with idiopathic inflammatory myopathy. Raj Tummala explained how this approach has been well-tolerated with no dose-limiting toxicity, cytokine-release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS). Data from patients with at least 1-month follow-up demonstrate early immunomodulatory-free clinical responses and a favourable safety profile.
Results were also shared for this agent from RESET-SLETM – an ongoing Phase 1/2 trial evaluating the safety and efficacy in six patients with non-renal systemic lupus erythematous (SLE) or lupus nephritis. Saira Sheikh informed the audience that – over follow-up of 1–9 months – clinical improvement has been observed in all patients, with multiple patients achieving DORIS remission or complete renal response. All remain free of immunosuppressants. In addition, resecabtagene autoleucel has been well-tolerated, with an acceptable safety profile.
Data for rapcabtagene autoleucel were also shared, from an open-label Phase 1/2 study in severe refractory SLE. Eric Morand showcased clinical, cellular kinetics, pharmacodynamics, and biomarker outcomes up to 12 months after treatment in 21 patients, with a new data-cut fresh for the congress presentation. The findings suggest that treatment resulted in marked improvement in disease activity, effective B cell depletion and recovery of naive B cell phenotype, and a safety profile that is in line with that reported for CD19-CAR-T therapy in autoimmune disease.
SLE was also the focus for Vaneet Sandhu, whose team has developed a CAR-T cell product candidate derived from a clonal master cell bank engineered from an induced pluripotent stem cell line. This can be used as a renewable source for the mass production of CAR-T cells made available off-the-shelf for broad patient access. Results were reported from the first three patients in a multi-centre, Phase 1 study, with preliminary data indicating a favourable safety profile, effective B cell depletion with reconstitution of more naïve B cells, and promising initial efficacy.
Qiong Fu presented on GC012F (AZD0120) – a CD19/B cell maturation antigen (BCMA) dual-targeting CAR-T evaluated in 10 patients with SLE. At Month 9, 70% had been able to stop glucocorticoids and 40% had also discontinued hydroxychloroquine. All patients achieved normalisation of complement level after CAR-T infusion, and 60% achieved persistent serological conversion of ANA, ENA, and anti-dsDNA antibodies. No ICANS or ≥Grade 3 CRS were reported. These findings suggest this dual approach can induce disease remission in refractory SLE, with an early favourable safety profile.
Few CAR-T treatment approaches have been carried out in patients with refractory rheumatoid arthritis, but this could represent an important avenue for people with difficult-to-treat disease. Zhu Chen reported on findings in three patients with disease refractory to multiple conventional and biologic agents. All patients achieved DAS28-CRP remission at 12 weeks post- infusion. Of note, rheumatoid factor disappeared in all three patients, and anti-cyclic citrullinated peptide disappeared in two patients and significantly decreased in the third. CAR-T infusion was well tolerated with no CRS or ICANS observed. This study shows for the first time the feasibility of a fourth-generation CAR-T cell treatment in difficult-to-treat rheumatoid arthritis.
Ioanna Minopoulou shared results for CAR-T therapy in ANCA-associated vasculitis, with a case study of a 52-year-old man with severe disease refractory to many lines of treatment. After infusion, CAR-T cells expanded rapidly, peaking on Day 14 and declining over 6 weeks. He developed Grade 1 CRS – which was managed with 3 doses of tocilizumab – and Grade 3 neutropenia, resolved with filgrastim. No ICANS, infections, or other toxicities occurred. Symptoms resolved and granulomas stabilised, and the patient remained symptom-free without immunosuppressive treatment despite the return of CD19+ B cells at 7 months.
Finally, Christina Bergmann, Dinesh Khanna and colleagues set out to describe the trajectories of these indexes in 12 patients before and after CD19-CAR-T treatment. The revised European Scleroderma Trials and Research Group Activity Index (EUSTAR-AI) and the American College of Rheumatology Composite Response Index (ACR CRISS) are composite scores to assess disease activity and treatment response in patients with diffuse cutaneous SSc. Results showed that the majority of patients improved on both EUSTAR-AI and ACR CRISS. Median time to achieve EUSTAR <2.5 (inactive disease) and ACR CRISS ≥0.6 (good response) was 211 and 80.5 days, respectively. However, both scores also showed distinct patterns and appeared to complement each other.
Taken together, these findings suggest the potential for CAR-T cell therapy and other B cell-depleting therapies to reset the immune system in multiple RMD, allowing patients to achieve meaningful clinical responses without immunosuppressive therapies.
Source
Merkt W, et al. Two years on persisting CD19.CAR-T cells and nintedanib: clinical response of systemic sclerosis-associated pulmonary fibrosis. Presented at EULAR 2025; OP0292. Ann Rheum Dis 2025; DOI: 10.1136/annrheumdis-2025-eular.E366.
Khanna D, et al. RESET-SScTM: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), A Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Systemic Sclerosis. Presented at EULAR 2025; OP0338. Ann Rheum Dis 2025; DOI: 10.1136/annrheumdis-2025-eular.B1131.
Mozaffar T, et al. RESET-MyositisTM: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), A Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Idiopathic Inflammatory Myopathies. Presented at EULAR 2025; OP0316. Ann Rheum Dis 2025; DOI: 10.1136/annrheumdis-2025-eular.B1119.
Sheikh S, et al. RESET-SLE: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Non-Renal SLE and Lupus Nephritis. Presented at EULAR 2025; OP0202. Ann Rheum Dis 2025; DOI: 10.1136/annrheumdis-2025-eular.B1162.
Morand E, et al. Clinical, Cellular Kinetics, Pharmacodynamics and Biomarker Data Up to 12 Months After YTB323 (Rapcabtagene Autoleucel), a Rapidly Manufactured CD19 CAR-T Therapy, From an Open-Label, Phase 1/2 Study in Severe Refractory SLE. Presented at EULAR 2025; OP0079. Ann Rheum Dis 2025; DOI: 10.1136/annrheumdis-2025-eular.B2009.
Sandhu V, et al. Treatment of Refractory Systemic Lupus Erythematosus with Off-the-Shelf iPSC derived Anti-CD19 CAR T-cell Therapy. Presented at EULAR 2025; OP0032. Ann Rheum Dis 2025; DOI: 10.1136/annrheumdis-2025-eular.B3091.
Wu C, et al. Preliminary results of CD19/BCMA Dual-Targeting FasTCAR-T Cells GC012F (AZD0120) in patients with refractory Systemic Lupus Erythematosus-an open-label single-arm study. Presented at EULAR 2025; OP0074. Ann Rheum Dis 2025; DOI: 10.1136/annrheumdis-2025-eular.B2439.
Chen Z, et al. T Fourth-generation chimeric antigen receptor T-cell therapy in difficult-to-treat rheumatoid arthritis. Presented at EULAR 2025; OP0291. Ann Rheum Dis 2025; DOI: 10.1136/annrheumdis-2025-eular.E123.
Minopoulou I, et al. Targeted B-cell therapy by anti-CD19 CAR T cells induces stable disease remission in treatment-refractory ANCA-associated vasculitis. Presented at EULAR 2025; OP0294. Ann Rheum Dis 2025; DOI: 10.1136/annrheumdis-2025-eular.E720.
Bergmann C, et al. Trajectories of the EUSTAR AI, ACR CRISS and Revised CRISS upon CD19.CART treatment in patients with diffuse cutaneous Systemic Sclerosis. Presented at EULAR 2025; OP0337. Ann Rheum Dis 2025; DOI: 10.1136/annrheumdis-2025-eular.B2253.
About EULAR
EULAR is the European umbrella organisation representing scientific societies, health professional associations and organisations for people with rheumatic and musculoskeletal diseases (RMDs). EULAR aims to reduce the impact of RMDs on individuals and society, as well as improve RMD treatments, prevention, and rehabilitation. To this end, EULAR fosters excellence in rheumatology education and research, promotes the translation of research advances into daily care, and advocates for the recognition of the needs of those living with RMDs by EU institutions.
Contact
EULAR Communications, communications@eular.org
Notes to Editors
EULAR Recommendations
EULAR School of Rheumatology
EULAR Press Releases
END
Cell-depleting treatment in severe RMD: New data
2025-06-13
ELSE PRESS RELEASES FROM THIS DATE:
Vasodilation in systemic sclerosis
2025-06-13
Most VVD in clinical trials have been shown to exert anti-fibrotic effects – but findings are mixed around whether they also improve pulmonary function tests and prevent progression of SSc-associated interstitial lung disease (ILD). A post-hoc analysis presented by Adela-Cristina Sarbu aimed to address this by assessing the impact of VVD on functional progression and all-cause mortality in people with SSc-ILD. Using data from the EUSTAR database, they looked at three different outcomes for 2,156 people receiving endothelin-receptor antagonists (ERA), phosphodiesterase-5 ...
New ideas in gout management
2025-06-13
Gout flares are associated with cardiovascular events. Treating gout to target serum urate level prevents flares, but whether such treatment can also prevent cardiovascular events is unknown. An abstract from Edoardo Cipolletta and colleagues explored whether achieving serum urate levels of less than 360 μmol/L within 1 year of the first prescription of urate-lowering therapy has an effect on the 5-year risk of major adverse cardiovascular events (MACE). The authors used English and Swedish primary-care data linked to hospitalisation and mortality records for over 116,000 patients. Overall, 16,201 patients had a MACE ...
Risk factors for progression in spondyloarthritis
2025-06-13
Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic musculoskeletal disease that predominantly affects the axial skeleton.1 axSpA is an umbrella term that comprises the whole spectrum of patients with and without radiographic sacroiliitis, and joint ASAS/EULAR recommendations were published in 2022.2 Radiographic sacroiliitis classifies patients as radiographic axSpA (r-axSpA) and those patients are at risk of spinal ankyloses. High disease activity has previously been linked to accelerated radiographic spinal progression in patients with early axSpA,3 but more information is needed.
Work presented at the 2025 annual ...
Patient experiences In JIA
2025-06-13
A systematic review aimed to assess the specific needs for adolescents and young adults with juvenile idiopathic arthritis (JIA). Data from 1,913 patients aged range 11–30 years found that the three most common general needs were around daily activities and involvement in treatment decisions – each cited by 66% - and social life, including family and sexual considerations, which affected 55%. Other key needs in increasing order of importance were mobility, future, education, disease management, and treatment. Of the studies that focused on mental health, the need for independence, emotional ...
Patient organizations: The partner by your side
2025-06-13
At the 2025 congress of EULAR – The European Alliance of Associations for Rheumatology – two abstracts were presented that showcase how patient organisations can help to support with education for people with an RMD.
The first looked at the idea of ‘introduction maps’. To do this, patient experts and healthcare professionals working with ReumaNet in Belgium researched the information needs of new RMD patients. The results suggested a need for high-quality information with one distribution ...
Nurses: A critical role for people with RMD
2025-06-13
New studies shared at the 2025 annual EULAR congress in Barcelona reinforce that position, highlighting the benefits that nurse-led care can bring for both patients and healthcare systems.
Nurse-led care and self-monitoring can both support treat-to-target (T2T) approaches.2,3 Combining self-monitoring with nurse support during the initiation of urate-lowering therapy in people with gout could help reduce physician visits and costs while maintaining or improving quality of care. Work shared by Jeffrey van der Ven looked at estimating the cost-effectiveness ...
Online information for patients needs guidance
2025-06-13
Recommendations stress that communication impacts treatment outcomes and shared decision-making between patients and physicians. Health literacy is an important aspect in this regard, and a person’s understanding of their condition can impact how they are able to use health information.2 There is growing evidence to suggest that internet-based information is an important tool for improving communication with healthcare professionals – and for many patients it plays a central role in their experience.3
New work presented at the 2025 annual EULAR ...
The many ways that AI enters rheumatology
2025-06-13
High-resolution computed tomography (HRCT) is the standard to diagnose and assess progression in interstitial lung disease (ILD), a key feature in systemic sclerosis (SSc). But AI-assisted interpretation has the potential to improve the quantification and characterisation of SSc-ILD, making it a powerful tool for monitoring. Francesca Motta offered new data from an observational study pitting AI-assisted analysis against two radiologists with expertise in thoracic imaging. Results showed that the AI outperformed visual scoring in assessing the progression of fibrosis in patients with SSc-ILD, and showed more significant correlation with values from pulmonary ...
Pregnancy outcomes in autoinflammatory disease
2025-06-13
To address this, a French multi-centre prospective pregnancy observational cohort was set up, to analyse disease activity, treatment, pregnancy outcomes, delivery, and neonatal health. The work – presented at the 2025 annual congress of EULAR – showcased findings from 97 women with an autoinflammatory disease. The most common diagnoses were FMF (81%), followed by undifferentiated systemic autoinflammatory diseases (USAID), tumour necrosis factor receptor-associated periodic syndrome (TRAPS), cryopyrin-associated periodic syndromes (CAPS), Still's disease, recurrent pericarditis, mevalonate kinase deficiency, A20 haploinsufficiency, and other ...
The value of physical activity for people with RMD
2025-06-13
Several sessions at the 2025 annual congress of EULAR, which took place in Barcelona, focused on the value of physical activity for people with a variety of RMD – as well as the potential barriers to implementing these programs in the real world.
Previous trials have demonstrated that long-standing, personalised supervised exercise therapy is more effective than usual care after 1 year in people with severe functional limitations due to rheumatoid arthritis (RA) or axial spondyloarthritis (axSpA).3,4 David Ueckert and colleagues set out to evaluate ...